Core Viewpoint - HCA Healthcare, Inc. is a leading U.S. healthcare provider with a market capitalization of $120.82 billion, focusing on high-quality patient care and innovative treatments [1] Stock Performance - HCA's stock has increased by 67.8% over the past 52 weeks and is up 15.7% year-to-date (YTD), although it is down 2.3% from its 52-week high of $552.90 reached on February 12 [2] - The stock has outperformed the broader S&P 500 Index, which gained 11.8% over the past 52 weeks but is down marginally YTD, and the State Street Health Care Select Sector SPDR ETF (XLV), which increased by 7.7% over the same period [3] Financial Results - HCA reported a 6.7% year-over-year (YOY) revenue increase to $19.51 billion for the fourth quarter, with an adjusted EPS of $8.01, up 28.8% YOY, exceeding Wall Street expectations [4] - For the current quarter, analysts expect HCA's EPS to rise by 11.2% YOY to $7.17, with projections of $30.20 for fiscal 2026 (up 7.1%) and $33.35 for fiscal 2027 (up 10.4%) [5] Analyst Ratings - Among 25 Wall Street analysts, the consensus rating for HCA's stock is a "Moderate Buy," consisting of 14 "Strong Buy" ratings, one "Moderate Buy," nine "Holds," and one "Strong Sell," indicating a slight decrease in bullish sentiment compared to three months ago [6]

Core Insights - HCA Healthcare, Inc. is a significant player in the healthcare services sector with a market capitalization of $107.7 billion and is set to announce its fiscal Q4 earnings for 2025 soon [1] Financial Performance - Analysts anticipate HCA to report a profit of $7.37 per share for the upcoming quarter, reflecting an 18.5% increase from $6.22 per share in the same quarter last year [2] - For the current fiscal year ending in December, HCA is expected to achieve a profit of $27.60 per share, which is a 25.7% increase from $21.96 per share in fiscal 2024, with further growth projected to $29.66 per share in fiscal 2026 [3] Stock Performance - HCA's shares have increased by 55.5% over the past 52 weeks, significantly outperforming the S&P 500 Index's 16% return and the State Street Health Care Select Sector SPDR ETF's 12.5% increase during the same period [4] Recent Developments - Following a better-than-expected Q3 earnings release, HCA's shares rose by 1.6%. The company reported total revenue of $19.2 billion, a 9.6% year-over-year increase, exceeding consensus expectations by 3.6%. Adjusted EPS improved by 42% from the previous year to $6.96, surpassing analyst estimates of $5.65 [5] - HCA has raised its fiscal 2025 guidance, now expecting revenue between $75 billion and $76.5 billion, and EPS between $27 and $28 [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for HCA, with 14 out of 25 analysts recommending "Strong Buy," one suggesting "Moderate Buy," nine indicating "Hold," and one advising "Strong Sell." The mean price target for HCA is $486.41, suggesting a 3% potential upside from current levels [6]